GlaxoSmithKline PLC ADR

GSK.US
Healthcare · Drug Manufacturers - General
53.71
+1.73 (+3.33%)
USD · NYSE

Company Information

Company Name
GlaxoSmithKline PLC ADR
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYSE
ISIN: US37733W2044
CIK: 0001131399
CUSIP: 37733W105
Currency: USD
Full Time Employees: 66,841
Phone: 44 20 8047 5000
Fiscal Year End: December
IPO Date: Jul 09, 1986
Description:

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Address:

79 New Oxford Street, London, United Kingdom, WC1A 1DG

People

Directors & Officers

Name Title Year Born
Ms. Julie Belita Brown A.C.A. CFO & Executive Director 1962
Ms. Emma Natasha Walmsley Executive Officer 1969
Dr. Jesse L. Goodman M.D., M.P.H. Scientific & Medical Expert 1951
Mr. Luke Victor Miels CEO & Director 1974
Ms. Shobie Ramakrishnan Chief Digital & Technology Officer 1971
Mr. Tony Wood Chief Scientific Officer and Head of R&D NA
Mr. Constantin Fest Senior VP & Head of Investor Relations 1977
Mr. James Ford Senior VP and Group General Counsel of Legal & Compliance NA
Mr. David Simon Redfern BSc (Hons), CA President of Corporate Development 1966
Ms. Roanne Parry Chief People Officer 1974

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 11, 2025 Plc Gsk N/A Purchase 1.47M $19.00 $27.93M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 67.66M Mar 31, 2026 3.38% $0.20 0.28%
Dodge & Cox 58.66M Mar 31, 2026 2.93% $1.78 -14.38%
Fisher Asset Management, LLC 34.52M Mar 31, 2026 1.72% $0.65 4.00%
PRIMECAP Management Company 25.20M Mar 31, 2026 1.26% $1.10 0.30%
Acadian Asset Management LLC 11.80M Mar 31, 2026 0.59% $0.92 1,169.89%
Wellington Management Company LLP 11.72M Mar 31, 2026 0.59% $0.12 -6.69%
Morgan Stanley - Brokerage Accounts 11.03M Mar 31, 2026 0.55% $0.04 89.25%
The Goldman Sachs Group Inc 9.59M Mar 31, 2026 0.48% $0.06 32.41%
JTC Employer Solutions Trustee Ltd 9.04M Mar 31, 2026 0.45% $41.69 -37.33%
Royal Bank of Canada 7.51M Mar 31, 2026 0.37% $0.07 -11.48%
T. Rowe Price Associates, Inc. 7.32M Mar 31, 2026 0.37% $0.05 -7.24%
State Street Corp 6.00M Mar 31, 2026 0.30% $0.01 -4.07%
Holocene Advisors, LP 5.52M Mar 31, 2026 0.28% $0.73 -32.01%
Mondrian Investment Partners Ltd 4.99M Mar 31, 2026 0.25% $4.12 -14.11%
Bank of Montreal 4.64M Mar 31, 2026 0.23% $0.10 78.46%
BMO Capital Markets Corp. 4.64M Mar 31, 2026 0.23% $0.10 78.46%
BlackRock Inc 3.55M Mar 31, 2026 0.18% $0.00 95.73%
Grantham, Mayo, Van Otterloo & Co., LLC 3.52M Mar 31, 2026 0.18% $0.50 0.95%
Hotchkis & Wiley Capital Management LLC 3.48M Mar 31, 2026 0.17% $0.59 -4.81%
Equity Investment Corp 3.22M Mar 31, 2026 0.16% $3.48 -21.64%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Dodge & Cox Stock I 33.78M 1.69% ▼ 21.40% Jun 30, 2026
2 Vanguard PRIMECAP Inv 18.15M 0.91% ▲ 0.03% Mar 31, 2026
3 Vanguard Wellington Inv 9.86M 0.49% ▼ 6.70% Mar 31, 2026
4 Strategic Advisers Fidelity US TtlStk 7.79M 0.39% ▲ 0.53% May 31, 2026
5 Fidelity Series Large Cap Stock 4.55M 0.23% ▲ 1.18% May 31, 2026
6 Fidelity Series Value Discovery 4.20M 0.21% ▲ 2.80% May 31, 2026
7 Vanguard PRIMECAP Core Inv 3.54M 0.18% ▲ 0.00% Mar 31, 2026
8 Dodge & Cox Balanced Composite 3.45M 0.17% ▼ 18.61% Jun 30, 2026
9 Dodge & Cox Balanced I 3.45M 0.17% ▼ 18.61% Jun 30, 2026
10 Fidelity Growth & Income 3.40M 0.17% ▲ 2.15% May 31, 2026

Financial Highlights

Market Cap: $102.84B
EBITDA: $11.43B
P/E Ratio: $13.50
PEG Ratio: $19.13
Book Value: $11.83
Dividend/Share: $0.67
Dividend Yield: 3.50%
Earnings/Share: $3.85
Profit Margin: 17.78%
Operating Margin: 36.28%
ROA (TTM): 10.02%
ROE (TTM): 40.91%
Revenue (TTM): $32.78B
Revenue/Share (TTM): $16.25
Earnings Growth (YOY): 8.40%
Revenue Growth (YOY): 1.50%

Valuation Metrics

Enterprise Value: $125.71B
Trailing P/E: 13.50
Forward P/E: 21.23

Shares Statistics

Shares Outstanding: 2.00B
Shares Float: 1.95B
% Insiders: 5.70%
% Institutions: 1,757.60%
Short % Float: 0.69%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$32.67B
Cost of Goods Sold
adjust
$-9.02B
Gross Profit
subtotal
$23.65B
SG&A
adjust
$-9.09B
R&D
adjust
$-7.53B
Operating Income
subtotal
$8.34B
Other / Non-Operating Items
adjust
$-2.62B
Net Income
subtotal
$5.72B

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GSK.US!